Literature DB >> 27571188

Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.

Giselle A Abruzzese1, Gloria E Cerrrone2, Juan M Gamez3, Mabel N Graffigna3, Susana Belli3, Gustavo Lioy4, Eduardo Mormandi3, Patricia Otero3, Oscar A Levalle3, Alicia B Motta1.   

Abstract

Polycystic ovary syndrome (PCOS) is an endocrine disorder. PCOS women are at high risk of developing insulin resistance (IR) and cardiovascular disorders since young age. We aimed to study the reliability of lipid accumulation product (LAP) and visceral adiposity index (VAI) as markers of metabolic disturbances (MD) associated with IR in young reproductive aged PCOS patients. We also evaluated the association between LAP and VAI and the presence of hyperandrogenism. In a cross-sectional study, 110 PCOS patients and 88 control women (18-35 years old) were recruited. PCOS patients were divided into 2 groups, as hyperandrogenic and non-hyperandrogenic considering the signs of hyperandrogenism (clinical or biochemical). Anthropometric measurements were taken and blood samples collected. Metabolic and anthropometric characteristics and their association with IR and associated MD were evaluated and LAP and VAI were calculated. LAP and VAI were compared with TC/HDL-c and TG/HDL-c to define the best markers of MD in this population. Independently of the phenotype, young PCOS patients showed high IR and dyslipidemia. Both LAP and VAI showed to be more effective markers to assess MD and IR in these young women than TG/HDL-c or TC/HDL-c [cut-off values: LAP: 18.24 (sensitivity: 81.43% specificity: 73.49%), positive predictive value (PPV): 75.0%, negative predictive value (NPV): 77.27%, VAI: 2.19 (sensitivity: 81.16% specificity: 72.15% PPV: 74.65% NPV: 72.22%)]. LAP and VAI are representative markers to assess MD associated with IR in young PCOS patients. All PCOS patients, independently of their androgenic condition, showed high metabolic risk. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27571188     DOI: 10.1055/s-0042-113463

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  16 in total

1.  Are visceral adiposity index and lipid accumulation product reliable indices for metabolic disturbances in patients with type 2 diabetes mellitus?

Authors:  Nebojsa Kavaric; Aleksandra Klisic; Ana Ninic
Journal:  J Clin Lab Anal       Date:  2017-06-20       Impact factor: 2.352

2.  Body Fat Indices as Effective Predictors of Insulin Resistance in Obstructive Sleep Apnea: Evidence from a Cross-Sectional and Longitudinal Study : BFI as Predictors of IR in OSA.

Authors:  Ruobing Wei; Zhenfei Gao; Huajun Xu; Cuiping Jiang; Xinyi Li; Yupu Liu; Jianyin Zou; Huaming Zhu; Hongliang Yi; Jian Guan; Shankai Yin
Journal:  Obes Surg       Date:  2021-02-10       Impact factor: 4.129

3.  Body fat indices as effective predictors of insulin resistance in obese/non-obese polycystic ovary syndrome women in the Southwest of China.

Authors:  Xin Huang; Qiuyi Wang; Tingting Liu; Tianjiao Pei; Dong Liu; Huili Zhu; Wei Huang
Journal:  Endocrine       Date:  2019-03-28       Impact factor: 3.633

4.  Evaluation of the relationship between serum ferritin and insulin resistance and visceral adiposity index (VAI) in women with polycystic ovary syndrome.

Authors:  Büşra Başar Gökcen; Yasemin Akdevelioğlu; Sultan Canan; Nuray Bozkurt
Journal:  Eat Weight Disord       Date:  2020-08-08       Impact factor: 4.652

5.  Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy.

Authors:  Kui Yao; Ce Bian; Xia Zhao
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

6.  Oxidative stress and metabolic markers in pre- and postnatal polycystic ovary syndrome rat protocols.

Authors:  Lady Serrano Mujica; Alessandra Bridi; Ricardo Della Méa; Vitor Braga Rissi; Naiara Guarda; Rafael Noal Moresco; Melissa Orlandin Premaor; Alfredo Quites Antoniazzi; Paulo Bayard Dias Gonçalves; Fabio Vasconcellos Comim
Journal:  J Inflamm Res       Date:  2018-05-15

7.  Oxidative stress and biochemical markers in prenatally androgenized sheep after neonatal treatment with GnRH agonist.

Authors:  Jandui Escariãoda Nóbrega; Joabel Tonelotto Dos Santos; Lady K Serrano-Mujica; Guilherme Bochi; Rafael Noal Moresco; Vitor Braga Rissi; Werner Giehl Glanzner; Felipe W Langer; Alfredo Quites Antoniazzi; Paulo Bayard Dias Gonçalves; Melissa O Premaor; Fabio V Comim
Journal:  J Inflamm Res       Date:  2019-03-06

8.  Lipid accumulation product independently correlate with hepatic steatosis quantified by controlled attenuation parameter in women with polycystic ovary syndrome.

Authors:  Silan Zheng; Meifeng Tong; Lianqin Dong; Chunmin Du; Xin Zheng; Liying Wang; Peiying Huang; Wei Liu; Mingzhu Lin; Changqin Liu
Journal:  Endocr Connect       Date:  2020-02       Impact factor: 3.335

9.  Telomere Length Differently Associated to Obesity and Hyperandrogenism in Women With Polycystic Ovary Syndrome.

Authors:  Mariela Edith Velazquez; Andrea L Millan; Mailén Rojo; Giselle Adriana Abruzzese; Silvina Ema Cocucci; Andrea Elena Iglesias Molli; Gustavo Daniel Frechtel; Alicia Beatriz Motta; Gloria Edith Cerrone
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-14       Impact factor: 5.555

10.  Lipid Accumulation Product Is More Related to Insulin Resistance than the Visceral Adiposity Index in the Maracaibo City Population, Venezuela.

Authors:  Valmore Bermúdez; Juan Salazar; Jorge Fuenmayor; Manuel Nava; Ángel Ortega; Pablo Duran; Milagros Rojas; Roberto Añez; Alejandra Rivas-Montenegro; Lissé Angarita; Maricarmen Chacín; Clímaco Cano; Manuel Velasco; Joselyn Rojas
Journal:  J Obes       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.